COMMERCIALIZING WORLD-CLASS CANCER INNOVATION
Seeding and scaling Ontario’s premiere entrepreneurial ventures for patients and the economy.
KEY SUCCESSES
Our investments have resulted in significant partnerships, clinical trials, job creation and leveraged financing for the province.
RECENT NEWS
Keep up to date on our investments and business developments in recent news stories and summaries.
-
FACIT’s Prospects Fund fuels women’s health and brain cancer therapies for Ontario patients
September 28, 2022 – September 28, 2022 – FACIT congratulates Ontario-based start-ups Hyivy Health and HDAX Therapeutics as the latest recipients of capital through its Prospects Oncology Fund. Selected among a top-tier pool of applicants, these Ontario-based innovations illustrate excellent potential to benefit patients with cancer.
-
FACIT’s David O’Neill shares strategy for Ontario intellectual property
June 16, 2022 – The paper “How to boost Ontario’s life sciences IP to help patients and the economy” discusses the importance of seed-stage investing and commercialization-venture partnerships to reap the benefits of taxpayers’ investment in post-secondary education and health research.
Read More from FACIT’s David O’Neill shares strategy for Ontario intellectual property
-
FACIT invests in OICR’s groundbreaking approaches to integrated drug discovery and cancer informatics
April 28, 2022 – April 27, 2022 – FACIT announced two recent strategic investments from its Prospects Oncology Fund in innovations arising from renowned cancer experts at the Ontario Institute for Cancer Research (OICR): Dr. Rima Al-awar, Head of Therapeutic Innovation and Drug Discovery, and Dr. Lincoln Stein, Head of Adaptive Oncology.
We were established by the Ontario Institute for Cancer Research (OICR) to support commercialization, technology transfer, and development activities. OICR conducts and enables world-class cancer research, filling a critical role as a pan-provincial connector of oncology researchers, resources and cancer innovation development. Together with OICR, we drive a shared vision to attract more R&D investment in Ontario and help the best oncology innovations reach the market and save lives.
FACIT is funded in part by the Government of Ontario through OICR